[The first experience with dabigatran antidote in the University Hospital Pilsen]

Dabigatran (Pradaxa, Boehringer Ingelheim) is the first direct oral thrombin (FIIa) inhibitor. It is indicated for thromboprophylaxis in patients undergoing elective total replacement hip or knee joint surgery or for the primary or secondary prophylaxis of elderly patients with non-valvular atrial fibrillation or for deep vein thrombosis and pulmonary embolism treatment and prophylaxis. Idarucizumab (Praxbind, Boehringer Ingelheim) is a specific monoclonal antibody fragment indicated in patients treated with dabigatran. It is recommended when reversal of anticoagulant effect of dabigatran is needed especially in cases of life-threatening bleeding, for emergency surgery or urgent procedures purposes. In this article, there is a summary of our clinical and laboratory experience with reversal effect of idarucizumab in our five patients.